Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, PR China.
Yueyang Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, PR China.
Pharm Biol. 2020 Dec;58(1):785-795. doi: 10.1080/13880209.2020.1803368.
(QMY) is a clinically used herbal formula for treating arteriosclerosis obliterans (ASO).
To evaluate the chemical constituents and effects of QMY on ASO rabbit model.
Forty-eight New Zealand rabbits were divided into six groups ( = 8): normal (normal rabbits treated with 0.5% CMC-Na), vehicle (ASO rabbits treated with 0.5% CMC-Na), positive (simvastatin, 1.53 mg/kg), and QMY treatment (300, 600, and 1200 mg/kg). ASO rabbit model was prepared by high fatty feeding, roundly shortening artery, and bovine serum albumin immune injury. QMY (300, 600 and 1200 mg/kg) was orally administered for 8 weeks. The effects and possible mechanisms of QMY on ASO rabbits were evaluated by pathological examination, biochemical assays, and immunohistochemical assays. The compositions of QMY were analysed using HPLC-Q-TOF-MS/MS analysis.
Compared to the vehicle rabbit, QMY treatment suppressed plaque formation and intima thickness in aorta, and decreased intima thickness, whereas increased lumen area of femoral artery. Additionally, QMY treatment decreased TC, TG and LDL, decreased CRP and ET, and increased NO and 6-K-PGF1α in serum. Furthermore, the potential mechanisms studied revealed that QMY treatment could suppress expression of TNF-α, IL-6, ICAM-1 and NF-κB in endothelial tissues, and increase IκB. In addition, HPLC analysis showed QMY had abundant anthraquinones, stilbenes, and flavonoids.
QMY has ameliorative effects on ASO rabbit, and the potential mechanisms are correlated to reducing inflammation and down-regulating NF-κB. Our study provides a scientific basis for the future application and investigation of QMY.
(QMY)是一种用于治疗动脉硬化闭塞症(ASO)的临床应用草药配方。
评估 QMY 对 ASO 兔模型的化学成分和作用。
48 只新西兰兔分为六组(每组 8 只):正常组(正常兔给予 0.5%CMC-Na)、模型组(ASO 兔给予 0.5%CMC-Na)、阳性组(辛伐他汀,1.53mg/kg)和 QMY 治疗组(300、600 和 1200mg/kg)。通过高脂饮食、环形缩短动脉和牛血清白蛋白免疫损伤制备 ASO 兔模型。QMY(300、600 和 1200mg/kg)灌胃 8 周。通过病理检查、生化测定和免疫组化测定评价 QMY 对 ASO 兔的作用及可能机制。采用 HPLC-Q-TOF-MS/MS 分析 QMY 的组成。
与模型兔相比,QMY 治疗组抑制主动脉斑块形成和内膜增厚,降低内膜厚度,增加股动脉管腔面积。此外,QMY 治疗组降低血清 TC、TG 和 LDL,降低 CRP 和 ET,增加血清 NO 和 6-K-PGF1α。进一步研究的潜在机制表明,QMY 治疗可抑制内皮组织 TNF-α、IL-6、ICAM-1 和 NF-κB 的表达,增加 IκB。此外,HPLC 分析表明 QMY 含有丰富的蒽醌、芪类和类黄酮。
QMY 对 ASO 兔具有改善作用,其潜在机制与减轻炎症和下调 NF-κB 有关。本研究为 QMY 的未来应用和研究提供了科学依据。